Diltiazem long-acting (Apo-Diltiazem): Brand change
Supply is ending for all strengths of Apo-Diltiazem brand long-acting diltiazem. We have secured alternatives for all 3 presentations.
120mg capsules – Accord (section 29)
We have secured a short-term supply of Accord brand 120 mg diltiazem hydrochloride capsules. It will be listed from 1 December 2021.
This brand is not Medsafe approved, it will need to be prescribed and supplied in line with section 29 of the Medicines Act.
Prescribing and supplying a medicine under section 29
Section 29 of the Medicines Act allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – such as doctors.
We know supplying a medicine under section 29 is not ideal. In this case, however, the alternative would be for patients to have no 120mg presentation of long-acting diltiazem.
We apologise for any inconvenience this causes.
180mg and 240mg capsules long-acting diltiazem
We listed Cardizem CD brand long-acting 180mg and 240mg diltiazem capsules on 1 October 2021. Apo-Diltizem CD will be delisted from the Schedule on 1 February 2022.
We consulted on this decision on in February 2021. We appreciated the feedback we received. You can read the full decision and a discussion of the feedback we received on our website.
We appreciate the time and effort of pharmacists and other health care professionals to support patients through brand changes for medicines.
Who to contact
Information about the discontinuation of immediate release diltiazem is also on our website, read the Dilzem discontinuation notice
If you have questions about the funding for diltiazem, email firstname.lastname@example.org